Obesity study: Maridebart cafraglutide
Official title Comparing the Extent to Which Maridebart Cafraglutide is Made Available in the Body of Participants Living With Overweight or Obesity After Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA)
ClinicalTrials.gov ID: NCT07908316
What this study is testing
What is Maridebart cafraglutide?
An investigational once‑daily injectable medicine being studied for obesity.
Also referred to as AMG 133, MariTide.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The study will look at how the drug is absorbed, distributed, metabolized, and eliminated in people who are overweight or have obesity after they stop taking a weekly GLP‑1 receptor agonist.
- Who it's for
- Adults who are overweight or have obesity and have been taking a weekly GLP‑1 receptor agonist.
- What's involved
- Participants will stop their current medication and start taking maridebart cafraglutide. They will have blood samples taken at various times to measure the drug levels.
- Time commitment
- The study lasts a few weeks, with several clinic visits for blood draws and monitoring.
- Phase 1: an early, usually small safety study
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 70
You may be able to join if
- 18 to 70 years of age.
- Body Mass Index (BMI) ≥ 25 at screening.
- BMI ≥ 23 for Asian participants at screening.
- Stable body weight (approximately 5% or less gain or loss) during the 4-week run-in period, unless the study doctor determines otherwise.
- Stable dose of weekly GLP-1RA.
You likely can't join if
- Type 1/Type 2 diabetes mellitus (DM).
- Obesity induced by other endocrine disorder (ex: Cushing's syndrome).
- History of malignancy in the last 5 tears except for nonmelanoma skin cancers, cervical, or breast ductal carcinoma in situ.
- Acute \& chronic pancreatitis within 1 year.
- Uncontrolled thyroid disease.
- Gastroparesis or gastric outlet obstruction.
See the full eligibility criteria
- 18 to 70 years of age.
- Body Mass Index (BMI) ≥ 25 at screening.
- BMI ≥ 23 for Asian participants at screening.
- Stable body weight (approximately 5% or less gain or loss) during the 4-week run-in period, unless the study doctor determines otherwise.
- Stable dose of weekly GLP-1RA.
- Stable gastrointestinal (GI) side effects.
- Contraception for females.
- Stable for 3 months if obstructive sleep apnea (OSA), hypertension, hyperlipidemia, and/or hypothyroidism.
- Willingness to follow trial procedures for the duration of the trial.
- Type 1/Type 2 diabetes mellitus (DM).
- Obesity induced by other endocrine disorder (ex: Cushing's syndrome).
- History of malignancy in the last 5 tears except for nonmelanoma skin cancers, cervical, or breast ductal carcinoma in situ.
- Acute \& chronic pancreatitis within 1 year.
- Uncontrolled thyroid disease.
- Gastroparesis or gastric outlet obstruction.
- Surgery for obesity in the last 6 months.
- Heart attack within 3 months.
- History of ischemic optic neuropathy.
- Positive HIV or certain positive Hepatitis B or hepatitis C.
- Current use of compounded weekly GLP-1RA.
- Previous participation in Maridebart cafraglutide trial.
- Alcohol or drug abuse.
- Pregnancy, breastfeeding, or planning to breastfeed.
The study team makes the final eligibility decision.
Where it is enrolling
- Phoenix, Arizona, United States
- Montclair, California, United States
- Daytona Beach, Florida, United States
- Hialeah, Florida, United States
- Maitland, Florida, United States
- Lexington, Kentucky, United States
- Knoxville, Tennessee, United States
- Dallas, Texas, United States
- Madison, Wisconsin, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 70 years. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Phoenix, Arizona, United States; Montclair, California, United States; Daytona Beach, Florida, United States; Hialeah, Florida, United States; Maitland, Florida, United States; Lexington, Kentucky, United States and 3 more locations. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.